OncoMatch/Clinical Trials/NCT06423911
Study of Olverembatinib (HQP1351) in Patients With CP-CML
Is NCT06423911 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including olverembatinib and Bosutinib for chronic myeloid leukemia.
Treatment: olverembatinib · Bosutinib — A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Chronic Myeloid Leukemia
Biomarker criteria
Required: BCR::ABL1 T315I mutation
Part B: T315I mutation at screening.
Excluded: BCR::ABL1 T315I mutation
For Part A only: T315I mutation at any time prior to starting study treatment.
Disease stage
Required: Stage CHRONIC PHASE
Diagnosis of CML-CP
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: BCR-ABL inhibitor
Previously treated with at least two approved TKIs
Cannot have received: BCR-ABL inhibitor (olverembatinib)
Previous treatment with or known / suspected hypersensitivity to olverembatinib or any of its excipients.
Cannot have received: BCR-ABL inhibitor (bosutinib)
Previous treatment with or known / suspected hypersensitivity to bosutinib or any of its excipients.
Lab requirements
Blood counts
adequate organ functions
Kidney function
adequate organ functions
Liver function
adequate organ functions
Patients with adequate organ functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06423911 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BCR-ABL inhibitor, BCR-ABL inhibitor disqualifies patients from enrollment.
Does this trial require BCR::ABL1?
Yes, BCR::ABL1 T315I mutation is a required biomarker for enrollment.
Are patients with BCR::ABL1 alterations eligible?
No. BCR::ABL1 T315I mutation is an exclusion criterion.
What disease stage is eligible?
Stage CHRONIC PHASE is required.
Is there an age limit?
Yes. Patients must be 99 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages